Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone.
OBJECTIVE
The goal of this study was to evaluate the effectiveness of maropitant (Cerenia(®)) in preventing vomiting after premedication with hydromorphone.


METHODS
Randomized, blinded, prospective clinical study.


METHODS
Eighteen dogs ASA I/II admitted for elective orthopedic surgical procedures. The dogs were a mixed population of males and females, purebreds and mixed breeds, 1.0-10.2 years of age, weighing 3-49.5 kg.


METHODS
Dogs were admitted to the study if they were greater than 1 year of age, healthy and scheduled to undergo elective orthopedic surgery. Dogs were randomly selected to receive one of two treatments administered by subcutaneous injection. Group M received 1.0 mg kg(-1) of maropitant, Group S received 0.1 mL kg(-1) of saline 1 hour prior to anesthesia premedication. Dogs were premedicated with 0.1 mg kg(-1) of hydromorphone intramuscularly. A blinded observer documented the presence of vomiting, retching and/or signs of nausea for 30 minutes after premedication.


RESULTS
All dogs in S vomited (6/9), retched (1/9) or displayed signs of nausea (2/9). None (0/9) of the dogs in M vomited, retched or displayed signs of nausea. Dogs in M had significantly fewer incidences of vomiting (p=0.0090), vomiting and retching (p=0.0023) and vomiting, retching and nausea (p<0.0001) when compared to S.


CONCLUSIONS
Maropitant prevents vomiting, retching and nausea associated with intramuscular hydromorphone administration in dogs.
Department of Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011-1250, USA. bhkraus@iastate.edu
Bonnie L
BL
Hay Kraus
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use*; D004283:Dog Diseases / Q000139:chemically induced / Q000517:prevention & control* / Q000601:surgery; D004285:Dogs / Q000601:surgery; D005260:Female; D004091:Hydromorphone / Q000008:administration & dosage / Q000009:adverse effects*; D007273:Injections, Intramuscular / Q000662:veterinary; D008297:Male; D011229:Preanesthetic Medication / Q000009:adverse effects*; D011812:Quinuclidines / Q000627:therapeutic use*; D014839:Vomiting / Q000517:prevention & control / Q000662:veterinary*
D000701:Analgesics, Opioid; D000932:Antiemetics; D011812:Quinuclidines; C518176:maropitant; D004091:Hydromorphone